ОБЗОР
МЕЖДУНАРОДНЫХ
ПЕРИОДИЧЕСКИХ
ИЗДАНИЙ

НОВОСТИ СВЕЖИЙ НОМЕР ОБ ИЗДАНИИ
Для специалистов по репродуктивному здоровью. PROdigest. Приложение к бюллетеню
prodigest prodigest prodigest prodigest prodigest
2015 vol1 2015 vol2 2015 vol3 2016 2017

Hepatic adenomas in adolescents and young women with endometriosis treated with norethindrone acetate.

Authors: Brady PC, Missmer SA, Laufer MR.
Publication date: 20170104
Journal: J Pediatr Adolesc Gynecol. 2016 Dec 23. pii: S1083-3188(16)30232-7. [Epub ahead of print]
DOI: 10.1016/j.jpag.2016.12.002

BACKGROUND:

Endometriosis-ectopic implantation of endometrial-like tissue-affects 10% of female adolescents and adults. First-line treatment includes progesterone-only (such as norethindrone acetate, NET-A) or combined estrogen/progestin oral contraceptive pills. Estrogen-containing contraceptives confer increased risk of hepatic adenomas, while the association with NET-A is very rarely reported.

CASE:

Three adolescents with Stage I-II endometriosis managed with NET-A (up to 15 mg/day for 28-78 months) were diagnosed with hepatic adenomas at ages 17-22 years. They previously received estrogen-containing medications, which were stopped > 24 months before diagnosis of hepatic adenoma.

SUMMARY AND CONCLUSION:

NET-A in a dose above 10 mg per day may be associated with increased risk for hepatic adenomas, likely due to peripheral conversion to ethinyl estradiol. Use of NET-A may not be advisable in patients with known hepatic adenomas.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.